CORD-19:932bcdd2f6c6d487386e8bf983e4874387771be1 / 301366-301684 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T53670","span":{"begin":0,"end":318},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"This suggests that autoimmune therapy in MS should begin as early as possible to have an optimum chance for success and indicates that once sufficient deficit is accumulated, targeting relapsing, immunological components of disease alone is unlikely to be sufficient to control progression based on a clinical outcome."}

{"project":"Epistemic_Statements","denotations":[{"id":"T651","span":{"begin":0,"end":318},"obj":"Epistemic_statement"}],"text":"This suggests that autoimmune therapy in MS should begin as early as possible to have an optimum chance for success and indicates that once sufficient deficit is accumulated, targeting relapsing, immunological components of disease alone is unlikely to be sufficient to control progression based on a clinical outcome."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T102","span":{"begin":0,"end":318},"obj":"Sentence"}],"text":"This suggests that autoimmune therapy in MS should begin as early as possible to have an optimum chance for success and indicates that once sufficient deficit is accumulated, targeting relapsing, immunological components of disease alone is unlikely to be sufficient to control progression based on a clinical outcome."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1858","span":{"begin":41,"end":43},"obj":"Disease"},{"id":"T1831","span":{"begin":41,"end":43},"obj":"Disease"}],"attributes":[{"id":"A1858","pred":"mondo_id","subj":"T1858","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A58515","pred":"mondo_id","subj":"T1831","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"}],"text":"This suggests that autoimmune therapy in MS should begin as early as possible to have an optimum chance for success and indicates that once sufficient deficit is accumulated, targeting relapsing, immunological components of disease alone is unlikely to be sufficient to control progression based on a clinical outcome."}